Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: An analysis of the CAESAR study

AIDS

Volumn 14, Issue 9, 2000, Pages 1111-1116

  Pillay, Deenan ^a   Cane, Patricia A ^a   Ratcliffe, Daina ^a   Atkins, Mark ^b   Cooper, David ^c  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Drug resistance; Hepatitis B virus; HIV 1; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME BLOOD LEVEL; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; VIRUS REPLICATION;

CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MICROBIAL; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 0033918771     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200006160-00007     Document Type: Article

References (39)

1. 1. Coates JA, Cammack N, Jenkinson HJ, et al. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992, 36:202-205.
2. 2. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991, 88:8495-8499.
3. 3. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263.
4. 4. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 on the development of the hepatitis B virus carrier state. J Infect Dis 1991, 163:1138-1140.
5. 5. Gilson RJC, Hawkins AE, Beecham MR. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997, 11:597-606.
6. 6. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997, 349:995-996.
7. 7. Benhamou Y, Dohin E, Lunei-Fabiani F, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients [letter]. Lancet 1995, 345:396-397.
8. 8. Schnittman SM, Pierce PF. Potential role of lamivudine (3TC) in the clearance of chronic hepatitis B virus infection in a patient with human immunodeficiency virus type 1 [letter]. Clin Infect Dis 1996, 23:638-639.
9. 9. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996, 125:705-712.
10. 10. Dore GJ, Cooper DA, Barrett C, et al. Dual efficacy of lamivudine on human immunodeficiency virus/hepatitis B virus coinfected patients from a randomised, controlled study (CAESAR). J Infect Dis 1999, 180:607-613.
11. 11. CAESAR Co-ordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997, 349:1413-1421.
12. 12. Schinazi RF, Lloyd RM, Nguyen M-H, et al. Characterisation of human immunodeficiency virus resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993, 37:875-881.
13. 13. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
14. 14. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistance to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
15. 15. Cao Q, Gu Z, Hiscott J, Dionne G, Wainberg MA. Generation of drug-resistance variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993, 37:130-133.
16. 16. Back NKT, Nijhuis M, Keulen W, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996, 15:4040-4049.
17. 17. Lange J, Hill A, Ait-Khaled M, et al. Does the M184V mutation affect the efficacy of HAART? Third Int Workshop on Drug Resistance and Treatment Strategies. San Diego, 1999 [abstract 116].
18. 18. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA 3001, a randomised trial of lamivudine (3TC) versus zidovudine (ZDV) versus 2DV plus 3TC in previously untreated patients. AIDS 1996, 10:975-981.
19. 19. Ling R, Mutimer D, Ahmed D, et al. Selection of mutations in the hepatitis B polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996, 24:711-713.
20. 20. Pillay D, Bartholomeusz A, Cane P, et al. Mutations in the hepatitis B DNA polymerase associated with antiviral resistance. Int Antiviral News 1998, 6:167-169.
21. 21. Lai C-L, Chien R-N, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998, 339: 61-68.
22. 22. Lai CL, Yuen MF. Clinical experience and follow-up with lamivudine in the Asian population. Presented at Third International Conference on Therapies for Viral Hepatitis, Maui, Hawaii. Antiviral Ther 1999, 4 (Suppl. 4):7.
23. 23. Ono-Nita SK, Kato N, Shiratori Y, et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999, 29:939-945.
24. 24. Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999, 29:1581-1586.
25. 25. Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine-resistance HBV infection in the liver transplant recipient. Gut 2000,46:107-113.
26. 26. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999, 28: 1032-1035.
27. 27. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999, 29:1836-1839.
28. 28. Yamanaka G, Wilson T, Innaimo S, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999, 43:190-193.
29. 29. De Clercq E. Perspectives for the treatment of hepatitis B virus infections. Int J Antimicrob Agents 1999, 12:81-95.
30. 30. Cane P, Mutimer D, Ratcliffe D, et al. Analysis of HBV quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antiviral Therapy 1999, 4: 7-14.
31. 31. Burroughs NJ, Pillay D, Mutimer D. Significance testing of clinical data using virus dynamics models with MCMC: application to emergence of lamivudine-resistant HBV. Proc Royal Soc Lond B 1999, 266:2359-2366.
32. 32. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998, 27:628-633
33. 33. Thibault V, Benhamou Y, Seguret C, et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients co-infected with HBV and human immunodeficiency virus. J Clin Micro 1999, 37:3013-3015.
34. 34. Main J, Brown JL, Howells C, et al. A double-blind, placebocontrolled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B infection. J Viral Hepatitis 1996, 3:211-215.
35. 35. Mutimer D, Pillay D, Cook P, et al. Selection of multi-resistant hepatitis B virus during sequential nucleoside analogue therapy. J Infect Dis 2000, 181 713-716.
36. 36. Nowak MA, Bonhoeffer S, Hill AM, et al. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996, 93:4398-4402.
37. 37. Burroughs NJ, Rand DA, Pillay D, Elias E, Mutimer D. Lamivudine-resistant mutants in liver transplant HBV patients: the consequences of quasi-species population structure for viral dynamics and eradication. In Therapies for Viral Hepatitis. Ed. by Schinazi RF, Sommodossi JP, Thomas H. Atlanta: Int Med Press; 1998: 335-343.
38. 38. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol. 1996, 70:7894-7899.
39. 39. Ono-Nita SK, Kato N, Shiratori Y, et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999, 103:1635-1640.